Eugit Therapeutics
ActiveEnabling Tissue Targeting of Therapies
What it does
Eugit Therapeutics targets the issue of non-specific drugs that cause toxicity and clinical trial failures, affecting millions with tissue-specific inflammatory diseases. TAGHOME delivers drugs with precision to diseased tissues using T cell receptors, enhancing safety and improving efficacy. Our initial focus is on the 3.1 million U.S. individuals with Inflammatory Bowel Disease, aiming to initiate clinical trials within two years. Cofounded by George Church (Harvard) and funded by Y Combinator (S22).
Next to it in Healthcare and bio · precision cell therapy targeting
- Cell BioEnginesSOSV SOSV IndieBio NY 06
'Off-the-shelf' Curative Cell Therapies
- Able SciencesSOSV SOSV IndieBio SF 15
RNA-based Off the Shelf Immune Cells for Cell Therapies
- Tinkeso TherapeuticsSOSV SOSV IndieBio NY 09
Cell therapy for oncology and autoimmune diseases.
- iOrgan BioSOSV SOSV IndieBio NY 2025 H2
Supplying Cells to Improve the Human Condition
- Modulari-TY Combinator W23
We teach your immune system to attack and cure cancer
- Nuntius TherapeuticsY Combinator W21
Cell-specific genetic medicines
- 株式会社センノ・セラピューティクスPlug and Play PnP 2026
ヒトiPS細胞由来の肝前駆細胞を活用した急性肝不全に対する細胞治療の開発
- Brown FoodsY Combinator W22
Making 'REAL' Cow and Human Milk!